Oncology Clinical Trials in Newark, DE

As of July 2026, 49 paid clinical trials are recruiting for Oncology in Newark, Delaware. Oncology trials evaluate immunotherapies, targeted therapies, antibody-drug conjugates, and combination regimens across solid tumors and blood cancers — from early-phase first-in-human studies to phase 3 registration trials. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 17, 2026.

Filter results

Filter results

State

City

Facility

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

49 clinical trials for Oncology

·Clear filters·↓ Download CSV

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

for Hematopoietic and Lymphatic System Neoplasm

Sites in Newark, Wilmington +178 more locations

Sponsor: Children's Oncology Group

Sex: Female·Age: Up to 39

Code: NCT06513962·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial

Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer

for Colorectal Cancer

Sites in Newark, Wilmington +140 more locations

Sponsor: Wake Forest University Health Sciences

Sex: All·Age: 60+

Code: NCT03998202·Recruiting·Listed Jun 2019

Apply to this trial

Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial

for Lymphoma

Sites in Newark +43 more locations

Sponsor: University of Rochester

Sex: All·Age: 18+·Accepts healthy volunteers

Code: NCT05006482·Phase 3·Recruiting·Listed Aug 2021

Apply to this trial

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

for Gastric Cancer

Drug: Sonesitatug vedotin

Sites in Newark +71 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT07431281·Phase 3·Recruiting·Listed Feb 2026

Apply to this trial

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

for Non-small Cell Lung Cancer (NSCLC)

Sites in Newark +47 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT07291037·Phase 3·Recruiting·Listed Dec 2025

Apply to this trial

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

for Hepatocellular Carcinoma

Drug: Rilvegostomig

Sites in Newark +30 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06921785·Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

for Non-small Cell Lung Cancer

Drug: Rilvegostomig

Sites in Newark +62 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06692738·Phase 3·Recruiting·Listed Nov 2024

Apply to this trial

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

for HER2-positive Gastric Cancer

Drug: Rilvegostomig

Sites in Newark +44 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06764875·Phase 3·Recruiting·Listed Jan 2025

Apply to this trial

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

for Head and Neck Squamous Cell Carcinoma

Drug: Petosemtamab

Sites in Newark +35 more locations

Sponsor: Merus B.V.

Sex: All·Age: 18+

Code: NCT06525220·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial

Conditions in Oncology (Newark, DE)

Non-small cell lung cancer (NSCLC)· 11 Breast cancer· 10 Solid tumor· 6 Multiple myeloma· 5 Colorectal cancer· 4 Ovarian cancer· 4 Non-Hodgkin lymphoma· 4 Cancer (any)· 4 Chronic lymphocytic leukemia (CLL)· 3 Mantle cell lymphoma· 3 Melanoma· 3 Metastatic breast cancer· 2 Gastroesophageal junction cancer· 2 Prostate cancer· 2 Endometrial cancer· 2 Myelofibrosis· 2 Follicular lymphoma· 2 Small lymphocytic lymphoma· 2 Head and neck cancer· 2 Triple-negative breast cancer· 1 HER2-positive breast cancer· 1 HER2-negative breast cancer· 1 Lung cancer· 1 Small cell lung cancer· 1 Metastatic colorectal cancer· 1 Rectal cancer· 1 Gastric cancer· 1 Esophageal cancer· 1 Liver cancer· 1 Biliary tract cancer· 1 Metastatic prostate cancer· 1 Bladder cancer· 1 Kidney cancer· 1 Glioblastoma· 1 Leukemia (other)· 1 Myelodysplastic syndromes (MDS)· 1 Myeloproliferative neoplasm· 1 Diffuse large B-cell lymphoma (DLBCL)· 1 Marginal zone lymphoma· 1 Burkitt lymphoma· 1 Hematologic malignancy· 1 Neuroendocrine tumors· 1